However, these studies have limitations, either by targeting theBCR-ABL fusion coding sequence, which is not the true genomic sequence ofBCR-ABL, or by ensuring that the resulting gene editing system is too large to be able to efficiently transduce into leukemia cells [21‒24]. This evidence concerns the gene ABL1 and leukemia.